Terms: = Prostate cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK
78 results:
1. Estimating the Prognostic Value of the Ntrk Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
Santi I; Vellekoop H; M Versteegh M; A Huygens S; Dinjens WNM; Mölken MR
Mol Diagn Ther; 2024 May; 28(3):319-328. PubMed ID: 38616205
[TBL] [Abstract] [Full Text] [Related]
2. Oncocytoid Salivary Tumors: Differential Diagnosis and Utility of Newly Described Immunohistochemistry.
Katabi N
Head Neck Pathol; 2024 Mar; 18(1):20. PubMed ID: 38502259
[TBL] [Abstract] [Full Text] [Related]
3. trka promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.
Zhang Y; Huang Z; Li K; Xie G; Feng Y; Wang Z; Li N; Liu R; Ding Y; Wang J; Yang J; Jia Z
J Exp Clin Cancer Res; 2024 Jan; 43(1):16. PubMed ID: 38200609
[TBL] [Abstract] [Full Text] [Related]
4. Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients.
Lang B; Cao C; Zhao X; Wang Y; Cao Y; Zhou X; Zhao T; Wang Y; Liu T; Liang W; Hu Z; Tian X; Zhang J; Yan Y
Eur J Med Res; 2023 Jul; 28(1):239. PubMed ID: 37461056
[TBL] [Abstract] [Full Text] [Related]
5. FBXO22 Mediates the NGF/trka Signaling Pathway in Bone Metastases in prostate cancer.
Zhang Y; Li W; Guo S; Wu Z; Zhang L; Liu Y; Li X; Guo X; Cao J; Yang C; Wang Z
Am J Pathol; 2023 Sep; 193(9):1248-1266. PubMed ID: 37301536
[TBL] [Abstract] [Full Text] [Related]
6. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Pereira-Salgado A; Anton A; Franchini F; Mahar RK; Kwan EM; Wong S; Shapiro J; Weickhardt A; Azad AA; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Steer C; Brown S; Gibbs P; Tran B; IJzerman M
Expert Rev Pharmacoecon Outcomes Res; 2023 Feb; 23(2):231-239. PubMed ID: 36541133
[TBL] [Abstract] [Full Text] [Related]
7. BDNF and its signaling in cancer.
Malekan M; Nezamabadi SS; Samami E; Mohebalizadeh M; Saghazadeh A; Rezaei N
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2621-2636. PubMed ID: 36173463
[TBL] [Abstract] [Full Text] [Related]
8. Correlation of ntrk1 Downregulation with Low Levels of Tumor-Infiltrating Immune Cells and Poor Prognosis of prostate cancer Revealed by Gene Network Analysis.
Bagherabadi A; Hooshmand A; Shekari N; Singh P; Zolghadri S; Stanek A; Dohare R
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627227
[TBL] [Abstract] [Full Text] [Related]
9. Microwave focal therapy of prostate cancer: a non-clinical study and exploratory clinical trial.
Boku H; Kaneko M; Yamada Y; Morinaga Y; Konishi E; Uno A; Ito-Ihara T; Yamada A; Horiguchi G; Teramukai S; Fujihara A; Shiraishi T; Yamada T; Ueda T; Matsugasumi T; Ohashi M; Horiuchi D; Inoue Y; Ukimura O
BJU Int; 2022 Dec; 130(6):776-785. PubMed ID: 35434902
[TBL] [Abstract] [Full Text] [Related]
10. The potential diagnostic accuracy of circulating microRNAs for prostate cancer: A meta-analysis.
Zhang WT; Zhang GX; Zhao RZ; Gao SS
Actas Urol Esp (Engl Ed); 2022 Apr; 46(3):138-149. PubMed ID: 35260368
[TBL] [Abstract] [Full Text] [Related]
11. Adult Ntrk-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements.
Tsai JW; Lee JC; Hsieh TH; Huang SC; Lee PH; Liu TT; Kao YC; Chang CD; Weng TF; Li CF; Lin JC; Liang CW; Su YL; Chang IY; Wang YT; Chang NY; Yu SC; Wang JC; Huang HY
Mod Pathol; 2022 Jul; 35(7):911-921. PubMed ID: 35149769
[TBL] [Abstract] [Full Text] [Related]
12. Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes.
Acosta AM; Sholl LM; Dickson BC; McKenney JK; Gordetsky JB; Pins MR; Marino-Enriquez A; Dong F; Dubuc AM; Cin PD; Fletcher CDM
Mod Pathol; 2021 Sep; 34(9):1763-1779. PubMed ID: 33986460
[TBL] [Abstract] [Full Text] [Related]
13. Loss of ephrin B2 receptor (EPHB2) sets lipid rheostat by regulating proteins DGAT1 and ATGL inducing lipid droplet storage in prostate cancer cells.
Morales A; Greenberg M; Nardi F; Gil V; Hayward SW; Crawford SE; Franco OE
Lab Invest; 2021 Jul; 101(7):921-934. PubMed ID: 33824421
[TBL] [Abstract] [Full Text] [Related]
14. South African guidelines for receptor radioligand therapy (RLT) with Lu-177-PSMA in prostate cancer.
Vorster M; Warwick J; Lawal IO; Du Toit P; Vangu M; Nyakale NE; Steyn R; Gutta AA; Hart G; Mutambirwa S; Ellmann A; Sathekge MM
S Afr J Surg; 2019 Dec; 57(4):45-51. PubMed ID: 31773936
[TBL] [Abstract] [Full Text] [Related]
15. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract] [Full Text] [Related]
16. A novel PTPRZ1-ETV1 fusion in gliomas.
Matjašič A; Zupan A; Boštjančič E; Pižem J; Popović M; Kolenc D
Brain Pathol; 2020 Mar; 30(2):226-234. PubMed ID: 31381204
[TBL] [Abstract] [Full Text] [Related]
17. Predictors of Response Outcomes for Research Recruitment Through a Central cancer Registry: Evidence From 17 Recruitment Efforts for Population-Based Studies.
Millar MM; Kinney AY; Camp NJ; Cannon-Albright LA; Hashibe M; Penson DF; Kirchhoff AC; Neklason DW; Gilsenan AW; Dieck GS; Stroup AM; Edwards SL; Bateman C; Carter ME; Sweeney C
Am J Epidemiol; 2019 May; 188(5):928-939. PubMed ID: 30689685
[TBL] [Abstract] [Full Text] [Related]
18. Incidence of surgical interventions for metastatic bone disease in the extremities: a population-based cohort study.
Skovlund Sørensen M; Hindsø K; Frederik Horstmann P; Troelsen A; Dalsgaard S; Fog T; Zimnicki T; Mørk Petersen M
Acta Oncol; 2019 Apr; 58(4):456-462. PubMed ID: 30632859
[TBL] [Abstract] [Full Text] [Related]
19. TRAF4-mediated ubiquitination of NGF receptor trka regulates prostate cancer metastasis.
Singh R; Karri D; Shen H; Shao J; Dasgupta S; Huang S; Edwards DP; Ittmann MM; O'Malley BW; Yi P
J Clin Invest; 2018 Jul; 128(7):3129-3143. PubMed ID: 29715200
[TBL] [Abstract] [Full Text] [Related]
20. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types.
Lacy S; Yang B; Nielsen J; Miles D; Nguyen L; Hutmacher M
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1071-1082. PubMed ID: 29687244
[TBL] [Abstract] [Full Text] [Related]
[Next]
